Prime Medicine Inc
PRME
ISIN null / Valor 122054714
Prime Medicine Inc
UMushroom community rating:
About company
Prime Medicine Inc is a biotechnology company focused on utilizing their innovative Prime Editing platform to address genetic diseases at their root cause. Their technology aims to replace faulty DNA with correct copies, potentially offering long-lasting cures for patients. Prime Editing is designed to be versatile, precise, and efficient, with the capability to target a wide range of disease-causing mutations across various organisms, organs, and cell types. The company believes that their approach will significantly enhance the impact of gene editing in therapeutic applications.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (06.11.2025):
Prime Medicine Inc reported its financial results for the Second Quarter 2025, showcasing notable improvements in R&D efficiency and a reduced net loss compared to the previous year. The company also highlighted significant capital raises, including a $144.2 million follow-on offering and an additional $24 million from the Cystic Fibrosis Foundation, as it transitions its strategic focus with a new CEO appointment and restructuring initiatives.
Financial Performance
For the quarter ended June 30, 2025, R&D expenses decreased to $41.4 million from $43.1 million year-over-year, while G&A expenses increased to $13.1 million mainly due to one-time severance and termination-related costs. Net loss narrowed to $52.6 million compared to $55.3 million in the corresponding quarter of 2024.
Capital and Liquidity
Prime Medicine Inc bolstered its financial position by completing an underwritten public offering, raising $144.2 million in gross proceeds, and securing up to $24 million from the Cystic Fibrosis Foundation. As of June 30, 2025, the company held $115.4 million in cash, cash equivalents, investments, and restricted cash, with guidance projecting a pro-forma cash position of $259.6 million to support operations into 2027.
Business and Strategic Updates
The company provided encouraging clinical data from its Phase 1/2 trial in Chronic Granulomatous Disease, evidencing proof-of-concept for Prime Editing, and announced plans for FDA engagements. Additionally, a strategic restructuring, including the appointment of Allan Reine, M.D. as CEO, underscores Prime Medicine Inc’s commitment to operational efficiency and advancing targeted genetic therapies.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
489 M
Market cap (USD)
2,745,314
Daily traded volume (Shares)
2.895 / 2.745
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
